JPWO2021209823A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021209823A5 JPWO2021209823A5 JP2022562954A JP2022562954A JPWO2021209823A5 JP WO2021209823 A5 JPWO2021209823 A5 JP WO2021209823A5 JP 2022562954 A JP2022562954 A JP 2022562954A JP 2022562954 A JP2022562954 A JP 2022562954A JP WO2021209823 A5 JPWO2021209823 A5 JP WO2021209823A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- cer
- effective
- high dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011055P | 2020-04-16 | 2020-04-16 | |
| US63/011,055 | 2020-04-16 | ||
| US202063092070P | 2020-10-15 | 2020-10-15 | |
| US63/092,070 | 2020-10-15 | ||
| US202063121640P | 2020-12-04 | 2020-12-04 | |
| US63/121,640 | 2020-12-04 | ||
| PCT/IB2021/000283 WO2021209823A1 (en) | 2020-04-16 | 2021-04-15 | Methods for treating acute conditions using lipid binding protein- based complexes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522889A JP2023522889A (ja) | 2023-06-01 |
| JP2023522889A5 JP2023522889A5 (https=) | 2024-04-25 |
| JPWO2021209823A5 true JPWO2021209823A5 (https=) | 2024-04-25 |
Family
ID=76197484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562954A Pending JP2023522889A (ja) | 2020-04-16 | 2021-04-15 | 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240033322A1 (https=) |
| EP (1) | EP4135747A1 (https=) |
| JP (1) | JP2023522889A (https=) |
| KR (1) | KR20230004605A (https=) |
| CN (1) | CN115427064A (https=) |
| AU (1) | AU2021256086A1 (https=) |
| CA (1) | CA3177243A1 (https=) |
| IL (1) | IL297336A (https=) |
| MX (1) | MX2022012969A (https=) |
| WO (1) | WO2021209823A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297046A (en) | 2020-04-16 | 2022-12-01 | Abionyx Pharma Sa | Treatment of kidney disease using cer-001 |
| KR20240018430A (ko) * | 2021-04-15 | 2024-02-13 | 아비오닉스 파마 에스에이 | 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용 |
| CA3247588A1 (en) * | 2022-04-06 | 2023-10-12 | Abionyx Pharma Sa | METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES |
| JP2025519606A (ja) * | 2022-06-10 | 2025-06-26 | アビオニクス ファーマ エスエー | 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法 |
| WO2023237927A2 (en) * | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes |
| WO2024150064A1 (en) * | 2023-01-13 | 2024-07-18 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
| CN116893215A (zh) * | 2023-03-17 | 2023-10-17 | 安徽省立医院(中国科学技术大学附属第一医院) | 一种用于监测car-t治疗之后crs进程的临床标志物及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5128318A (en) | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
| GB8712540D0 (en) | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
| US5220043A (en) | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| JP3754072B2 (ja) | 1994-03-22 | 2006-03-08 | リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド | 摂食抑制ペプチド |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| AU2001257173B2 (en) | 2000-04-21 | 2005-09-22 | Amgen Inc. | Apo-ai/aii peptide derivatives |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7144862B2 (en) | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| EP2343317A1 (en) | 2000-11-10 | 2011-07-13 | F. Hoffmann-La Roche Ltd. | Apolipoprotein analogues |
| US7217785B2 (en) | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| CA2457840C (en) | 2001-08-20 | 2011-10-11 | Zlb Bioplasma Ag | Hdl for the treatment of stroke and other ischemic conditions |
| US7223726B2 (en) | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
| AU2003239489A1 (en) | 2002-05-17 | 2003-12-02 | Esperion Therapeutics, Inc. | Method of treating dyslipidemic disorders |
| EP1545576A2 (en) * | 2002-07-30 | 2005-06-29 | Esperion Therapeutics Inc. | Methods of using non-human animal apoliprotein a-i protein |
| EP2314285B2 (en) | 2003-02-14 | 2019-09-18 | Children's Hospital & Research Center at Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
| CN101076541A (zh) | 2004-07-16 | 2007-11-21 | 塔夫茨大学信托人 | 载脂蛋白a1模拟物及其用途 |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| AU2006282722A1 (en) | 2005-08-26 | 2007-03-01 | Cerenis Therapeutics Holdings S.A. | Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria |
| US8541236B2 (en) | 2006-12-08 | 2013-09-24 | University Of Washington | Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls |
| WO2008104890A2 (en) | 2007-02-28 | 2008-09-04 | Cerenis Therapeutics Holding Sa | Compositions and methods for producing apolipoprotein |
| US9173890B2 (en) | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| EA201070517A1 (ru) | 2007-10-23 | 2010-12-30 | Дзе Кливленд Клиник Фаундейшн | Устойчивый к окислителям аполипопротеин а-1 и пептиды-миметики |
| LT2939683T (lt) | 2009-02-16 | 2017-03-27 | Cerenis Therapeutics Holding Sa | Apolipoproteino a-i mimetikai |
| US20130137628A1 (en) | 2010-05-11 | 2013-05-30 | Esperion Therapeutics, Inc. | Dimeric Oxidation-Resistant Apolipoprotein A1 Variants |
| EP2673296B1 (en) * | 2011-02-07 | 2018-10-24 | Cerenis Therapeutics Holding SA | Lipoprotein complexes and manufacturing and uses thereof |
| JP6438417B2 (ja) | 2013-03-15 | 2018-12-12 | セレニス セラピューティクス ホールディング エスアー | スフィンゴミエリンおよびジヒドロスフィンゴミエリンの合成のための方法 |
| US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| EP2853259A1 (en) * | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| WO2015173633A2 (en) | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| WO2018029505A1 (en) * | 2016-08-11 | 2018-02-15 | Cerenis Therapeutics Holding Sa | Cer-001 therapy for treating familial primary hypoalphalipoproteinemia |
| FR3100715B1 (fr) * | 2019-09-12 | 2023-09-29 | Francais Du Sang Ets | Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte |
-
2021
- 2021-04-15 KR KR1020227039569A patent/KR20230004605A/ko active Pending
- 2021-04-15 AU AU2021256086A patent/AU2021256086A1/en active Pending
- 2021-04-15 MX MX2022012969A patent/MX2022012969A/es unknown
- 2021-04-15 IL IL297336A patent/IL297336A/en unknown
- 2021-04-15 JP JP2022562954A patent/JP2023522889A/ja active Pending
- 2021-04-15 WO PCT/IB2021/000283 patent/WO2021209823A1/en not_active Ceased
- 2021-04-15 CA CA3177243A patent/CA3177243A1/en active Pending
- 2021-04-15 US US17/918,641 patent/US20240033322A1/en active Pending
- 2021-04-15 EP EP21728972.7A patent/EP4135747A1/en active Pending
- 2021-04-15 CN CN202180028796.XA patent/CN115427064A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arana et al. | Mucormycosis associated with COVID‐19 in two kidney transplant patients | |
| Vitiello et al. | Colchicine and SARS-CoV-2: management of the hyperinflammatory state | |
| Meduri et al. | Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature | |
| Reisch et al. | Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function | |
| Wing et al. | Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis | |
| US6299872B1 (en) | Combination therapy for chronic hepatitis c infection | |
| JP2020002171A5 (https=) | ||
| Brubaker et al. | Alternative treatment options for atrioventricular-nodal-reentry tachycardia: an emergency medicine review | |
| JPWO2021209823A5 (https=) | ||
| Pottage et al. | Treatment of human immunodeficiency virus—related thrombocytopenia with zidovudine | |
| JP2025081437A5 (https=) | ||
| Markatseli et al. | Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study | |
| Schürmann et al. | Safety and efficacy of liposomal amphotericin B in treating AIDS-associated disseminated cryptococcosis | |
| Fischl | Antiretroviral therapy in combination with interferon for AIDS-related Kaposi's sarcoma | |
| Hii et al. | Successful treatment of systemic blastomycosis with high-dose ketoconazole in a renal transplant recipient | |
| JP2016153402A (ja) | Ｃ型肝炎ウイルス感染症の新規治療 | |
| Miyata et al. | Rebamipide enemas–new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis | |
| CN117651556A (zh) | 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案 | |
| Rodríguez | Management of the adverse effects of lenalidomide in multiple myeloma | |
| Tinone et al. | Anticoagulation and stroke | |
| Kodama et al. | A New Scoring System to Predict the Efficacyof Steroid Therapy for Patients With Active Myocarditis A Retrospective Study | |
| Pearlman et al. | IMPROVED VIROLOGIC RESPONSE RATES WITH TREATMENT EXTENSION TO 72 WEEKS OF PEGINTERFERON ALFA-2B PLUS WEIGHT-BASED RIBAVIRIN IN A DIFFICULT-TO-TREAT POPULATION OF GENOTYPE 1-INFECTED SLOW RESPONDERS: 343 | |
| JPWO2023186808A5 (https=) | ||
| Iskierka-Jażdżewska et al. | Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia | |
| Bussone et al. | Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks |